Bavarian Nordic CEO Hopes Chordoma Vaccine Can Be Launched By Mid-2020
Executive Summary
Danish vaccine specialist's BN-Brachyury has been granted orphan drug designation by the FDA for treating chordoma.
You may also be interested in...
Bavarian Nordic CEO Says Likely To Sell Imvamune Priority Review Voucher
Danish group believes its smallpox vaccine will get approved, generate a transferable priority review voucher, and replace the current US-licensed replicating smallpox vaccine ACAM2000.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.